G-BA Benefit Assessment Watch — German AMNOG Tracker

Daily delta monitor of every G-BA Nutzenbewertung decision (German AMNOG, §35a SGB V) — the regulatory gate that decides what every new drug is allowed to cost in Germany. Webhook delivery per Beschluss.

For German Market Access, Pharma Pricing Strategy, HEOR, and Competitive Intelligence teams.

---

What this Actor does

Data source: g-ba.de/bewertungsverfahren/nutzenbewertung/ — the public Gemeinsamer Bundesausschuss Verfahren index. No login, no API key.

On each scheduled run:

1. Fetches the listing page → ~30 most-recent Verfahren-IDs.
2. Fetches each detail page → parses Wirkstoff, Indikation, Verfahrensnummer (D-XXX), all linked Beschluss PDFs (BAnz, Tragende Gründe, ZD).
3. Computes a stable identity per Verfahren (verfahrenId + most-recent Beschluss-date) and diffs against the seen-set in its KV store.
4. Pushes only new or amended Beschlüsse to the dataset — never duplicates.
5. Optionally fires a HMAC-signed webhook for every new Beschluss.

Output conforms to the unified azureblue/medical-core envelope so you can join G-BA Beschlüsse alongside EMA approvals and FDA recalls in one warehouse table.

---

Use Cases

1. Pharma launch-pricing strategy

A pharma pricing-strategy lead launching in Germany monitors every G-BA Beschluss that names a competitor in the same therapy area. Each Beschluss directly drives GKV-Spitzenverband negotiations and therefore the comparator price for THEIR launch. A single Beschluss can shift the launch price by 15-40% — having the alert within hours instead of finding it via a colleague's email digest is worth the entire annual subscription.

2. HEOR evidence-pack updates

A HEOR team prepares dossiers for AMNOG submissions. Each new Beschluss publishes the Tragende Gründe — the formal G-BA reasoning. Auto-archiving these PDFs against an internal indication taxonomy means the HEOR evidence library is current the day a Beschluss is published, not when someone manually downloads the PDF weeks later.

3. Market-access CI on competitor portfolios

A CI analyst tracks the AMNOG status of 8 competitor molecules in oncology. Filter the actor with substanceFilter: "pembrolizumab" (one run per competitor) — webhook into Slack. Detects benefit-rating downgrades and indication amendments the same business day, vs. ~3-6 weeks via trade-press monitoring.

---

Output (sample item)

{
  "scrapedAt": "2026-05-14T07:00:00.000Z",
  "sourceUrl": "https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1000/",
  "sourceDomain": "g-ba.de",
  "actorVersion": "1.0.0",
  "dataHash": "8a2f...d0",

  "regulator": "G_BA",
  "alertType": "benefit-assessment",
  "recordId": "1000",
  "changeKind": "new",

  "activeSubstance": "Nivolumab",
  "indication": "Neues Anwendungsgebiet: Melanom (Stadium IIB oder IIC), adjuvante Therapie, ≥ 12 Jahre, Monotherapie",
  "publishedAt": "2024-07-18",
  "effectiveAt": "2024-07-18",
  "summary": "G-BA Nutzenbewertung D-982: Nivolumab (Neues Anwendungsgebiet: Melanom ...). Beschluss 2024-07-18.",

  "documents": [
    { "kind": "BAnz-Beschluss", "url": "https://www.g-ba.de/downloads/.../2024-07-18_AM-RL-XII_Nivolumab_D-982_BAnz.pdf", "title": "Beschluss (Bundesanzeiger)" },
    { "kind": "TrG",            "url": "https://www.g-ba.de/downloads/.../2024-07-18_AM-RL-XII_Nivolumab_D-982_TrG.pdf",  "title": "Tragende Gründe" },
    { "kind": "gba-page",       "url": "https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1000/", "title": "G-BA Verfahren overview" }
  ],
  "extras": {
    "verfahrenId": "1000",
    "verfahrensnummer": "D-982",
    "benefitRating": null,
    "benefitRatingCode": null,
    "documentCount": 38
  }
}

Webhook payload

If you set webhookUrl:

{
  "eventId": "8a2f...d0",
  "eventType": "gba.benefit-assessment",
  "actor": "g-ba-benefit-assessment-watch",
  "emittedAt": "2026-05-14T07:00:01.123Z",
  "schemaVersion": 1,
  "data": { /* the alert object above */ }
}

X-Azureblue-Signature: sha256=<hex> header included if webhookSecret is set.

---

Pricing

Event	Price	When it fires
Monthly subscription	$79	Once per calendar month, on first delta-mode run — covers unlimited monitoring within the month
Per Beschluss	$0.02	Per new or amended Verfahren pushed to the dataset

Trial mode (mode: "trial"): 5 Verfahren, no charges, no state writes. Use to verify your filter scoping before subscribing.

Typical Market Access buyer: ~5-15 Beschlüsse/month on a competitive portfolio → $79 + $0.30/mo ≈ $80 all-in. Compare to: a single mis-anticipated AMNOG rating costing €15m–€100m on a launch price ceiling.

---

v1 limitations / v1.1 roadmap

• Benefit rating (erheblicher / beträchtlicher / geringer / nicht belegt) is null in v1 — the rating phrase lives in the BAnz/TrG PDF text, not in g-ba.de HTML. The PDF links are surfaced in documents[] so your team can click through, but the rating is not yet a queryable field.
• v1.1: PDF text parsing of the BAnz to populate extras.benefitRating and extras.benefitRatingCode automatically. ETA depends on PDF parsing performance — opt-in flag once available.
• v1.2: IQWiG report cross-link (the IQWiG benefit assessment that G-BA bases its Beschluss on) — the evidence behind the decision.

---

Compliance

• Public-data only — sourced from g-ba.de, the German federal HTA authority's public Verfahren register. No login walls, no PHI, no paywalled content.
• GDPR Art. 6(1)(f) — Beschluss content is published in the Bundesanzeiger as German federal law; downstream use as legitimate pharma market-access intelligence is the buyer's responsibility under GDPR.
• Rate-limited scraping — 800ms between Verfahren detail requests. G-BA is a single-region public-sector site; we keep traffic gentle.

---

Sister Actors — complementary coverage from azureblue

• ema-drug-approval-watch — upstream EU regulatory event that triggers most German AMNOG processes
• fda-drug-approval-watch — same alert schema, US drug-approval + recall side
• pubmed-kol-profile-builder — find the German KOLs publishing on the same indication the Beschluss covers
• cochrane-review-scraper — the systematic-review evidence base feeding IQWiG / G-BA assessments
• clinical-trials-scraper — the trial pipeline behind the substances heading into G-BA assessment

---

Changelog

See CHANGELOG.md in this Actor.